An integrated bioinformatics approach for identifying genetic markers that predict cerebrospinal fluid biomarker p-tau181/Aβ1-42 ratio in ApoE4-negative mild cognitive impairment patients

Manuscript Number: 

14-2118R2

Author(s): 
Anders Bresell, Kina Höglund, Thibaud Lebouvier, Mattias Rantalainen, Hugh Salter, Ying Sun

Disclosures

Anders Bresell

  • Nothing to Disclose

Kina Höglund

  • Nothing to Disclose

Thibaud Lebouvier

  • Nothing to Disclose

Mattias Rantalainen

  • Nothing to Disclose

Hugh Salter

  • Equity:
    Shareholder in AstraZeneca AB c 20000 USD
    Sponsors:
    Former employee of AstraZeneca AB, employed during the course of this research

Ying Sun

  • Sponsors:
    I am employed as post-doctoral research fellow by AstraZeneca, a pharmaceutical company.